Drug Profile
Research programme: topoisomerase inhibitors - Allarity Therapeutics
Alternative Names: TOP1-inhibitor - Allarity Therapeutics; TOP2-inhibitor liposomal-GSH - Allarity TherapeuticsLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Allarity Therapeutics
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer